Report
EUR 13.92 For Business Accounts Only

TAISHO PHARM. reduces its risk exposure and slightly improves to Neutral

The independent financial analyst theScreener just allocated a lower risk rating to TAISHO PHARM. (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as defensive. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date January 25, 2022, the closing price was JPY 5,580.00 and its expected value was estimated at JPY 5,492.22.
Underlying
Taisho Pharmaceutical Holdings Co. Ltd.

Taisho Pharmaceutical Holdings is a pharmaceutical company based in Japan. Co.'s operations are organized along two business segments: the Self-Medication Operation group and the Prescription Pharmaceutical Operation Group. The Self-Medication segment conducts research & development, manufacturing and sales of OTC drugs, foods for specified health use and general medical and hygiene supplies. The Prescription Drug Operation segment conducts research & development, manufacturing and sales of ethical drugs. Co. is also involved in the provision of insurance services, logistics services, printing services, hotel management operations, as well as real estate leasing and management services.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch